Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091386 · ClinicalTrials.gov registry record
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
A clinical trial of Hemophilia A, sponsored by Bayer.
- Completed
- Registry status
- 10
- Enrollment target
- 8
- Study locations
NCT04091386 is a study of Hemophilia A that has completed, run by Bayer. The registered enrollment target is 10 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT04091386, a study of Hemophilia A, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 8
- Study locations
Study Summary
In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small device measuring daily active time. Researcher will compare these physical activity data with patient's clinical data including bleeding events to gain information on how bleeding levels are related to the activity level of the patients. The study aims to enroll about 80 patients who are at the same time also participating in the HEM-POWR study (NCT03932201) evaluating the effectiveness and safety of damoctocog alfa pegol.
Conditions Studied
Interventions
- DRUG Damoctocog alfa pegol (Jivi, BAY94-9027)
Study Locations (8)
Other
- Many Locations - Multiple Locations
- Many Locations - Multiple Locations
- Many Locations - Multiple Locations
- Many Locations - Multiple Locations
- Many Locations - Multiple Locations
- Many Locations - Multiple Locations
California
- Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders - Orange
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2024-07-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091386
The ClinicalTrials.gov registry entry for NCT04091386 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (89% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Damoctocog alfa pegol (Jivi, BAY94-9027) is the first listed.
NCT04091386 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04091386 about?
NCT04091386 is a clinical study titled "Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)". In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small device measuring daily active time. Researcher will compare these physical activity data with patient...
What is the current status of trial NCT04091386?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2021-06-10. Estimated completion is 2024-07-05.
What conditions does trial NCT04091386 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT04091386?
The interventions under investigation include: Damoctocog alfa pegol (Jivi, BAY94-9027) (DRUG).
Who is sponsoring clinical trial NCT04091386?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04091386 being conducted?
This trial has 8 study locations across California, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.